11/13
08:06 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
11/13
05:02 am
vrdn
Rating for VRDN
Low
Report
Rating for VRDN
11/13
05:02 am
vrdn
Rating for VRDN
Low
Report
Rating for VRDN
10/28
08:25 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
10/28
08:04 am
vrdn
Rating for VRDN
Low
Report
Rating for VRDN
10/28
08:04 am
vrdn
Rating for VRDN
Low
Report
Rating for VRDN
9/26
12:58 pm
vrdn
Rating for VRDN
Low
Report
Rating for VRDN
9/19
10:55 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $44.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $44.00 price target on the stock.
9/19
10:55 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $44.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $44.00 price target on the stock.
9/19
10:09 am
vrdn
Rating for VRDN
Low
Report
Rating for VRDN
9/19
10:09 am
vrdn
Rating for VRDN
Low
Report
Rating for VRDN
9/13
09:53 am
vrdn
Rating for VRDN
Low
Report
Rating for VRDN
9/13
09:53 am
vrdn
Rating for VRDN
Low
Report
Rating for VRDN
9/12
11:45 am
vrdn
Rating for VRDN
Low
Report
Rating for VRDN
9/12
11:45 am
vrdn
Rating for VRDN
Low
Report
Rating for VRDN
9/12
11:45 am
vrdn
Rating for VRDN
Low
Report
Rating for VRDN
9/11
07:04 am
vrdn
Rating for VRDN
Medium
Report
Rating for VRDN
9/11
07:04 am
vrdn
Rating for VRDN
Medium
Report
Rating for VRDN
9/10
02:06 pm
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Medium
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
9/10
11:43 am
vrdn
Rating for VRDN
High
Report
Rating for VRDN
8/30
12:16 pm
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.
8/30
11:23 am
vrdn
Rating for VRDN
Low
Report
Rating for VRDN
8/30
11:23 am
vrdn
Rating for VRDN
Low
Report
Rating for VRDN
8/28
09:18 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $35.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $35.00 price target on the stock.
8/28
09:18 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $35.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $35.00 price target on the stock.